Bayer's Tumor-Agnostic Targeted Therapy Vitrakvi (Larotrectinib) Approved in Japan for NTRK Fusion-Positive Cancers

April 07, 2021 News /BioValleyBIOON/ --Bayer(Bayer) recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved its precision oncology drug Vitrakvi (larotrectinib), an oral TRK inhibitor specifically indicated for the treatment ofTumorpediatric and adult patients with advanced or metastatic solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Currently, Vitrakvi has been approved in multiple countries and regions worldwide, including the United States, the European Union, and the United Kingdom, with applications in other regions either underway or planned.

Vitrakvi demonstrates high response rates, durable responses, and a favorable safety profile in adult and pediatric patients with TRK fusion cancers. In primary central nervous system (CNS)TumorTherapeutic responses and high disease control rates were also observed in patients with CNS metastases.

The approval and market launch of Vitrakvi will provide Japanese patients and physicians with a highly selective therapy specifically designed for adult and pediatric TRK fusion cancers, with the potential to significantly improve treatment outcomes regardless of tumor type or patient age. Previously, anticancer drugs were primarily used for cancers in specific body sites, whereas Vitrakvi was developed specifically for the treatment of patients with TRK fusion cancers, regardlessTumorWhere it originates in the body. Vitrakvi represents a significant advancement in combating this rare cancer, as it will replace costly treatments that are not specifically targeted to this type of cancer and have not demonstrated efficacy and safety in this patient population.

Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer Pharmaceuticals, stated: “Therapies that directly target genomic abnormalities driving tumor growth, such as Vitrakvi, can provide value to patients and physicians in Japan, with the potential to significantly improve treatment outcomes regardless of tumor type or patient age. This approval further underscores the importance of high-quality and accessible genomic testing to more precisely identify those most likely to benefit from therapy targeting NTRK gene fusions.”Tumorpatients. It supports clinicians in delivering the right, effective, and safe treatment to the right patient at the right time.”

In Japan, the approval of Vitrakvi was based on pooled data from a total of 125 patients enrolled in the Phase I trial in adult patients, the Phase II NAVIGATE trial in adult and adolescent patients, and the Phase I/II SCOUT trial in pediatric patients. In these trials, Vitrakvi was investigated for the treatment of more than 20 types of solid tumors with diverse histologies.Tumor, including lung cancer and thyroid cancer,Melanoma, gastrointestinal stromal tumors, colorectal cancer, cholangiocarcinoma, soft tissue sarcoma, salivary gland carcinoma, and infantile fibrosarcoma.

The results demonstrated that Vitrakvi treatment yielded high response rates, with rapid and durable responses. Specific data are as follows: (1) Analysis of the patient population from the NAVIGATE trial showed an overall response rate (ORR) of 65.2%, including a complete response (CR) rate of 16.9%; (2) Data from the SCOUT trial indicated an ORR of 88.9% and a CR rate of 22.2%. Safety data from 116 patients in the NAVIGATE trial and 73 patients in the SCOUT trial demonstrated that Vitrakvi has a favorable safety profile.

Viktarvy demonstrates clinically meaningful improvements in quality of life (QoL) for adult and pediatric patients with TRK fusion-driven cancer. In two global, multicenterClinical TrialAmong them, 60% of adult patients reported an improvement in the EORTC QLQ-C30 global health status score. For pediatric patients, 76% reported an improvement in the total PedsQL score.

Molecular Structural Formula of Larotrectinib

TRK fusion cancers are generally rare, can affect both children and adults, and occur with varying frequencies across different tumor types. TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing an altered TRK protein. The altered protein, or TRK fusion protein, becomes constitutively active or overexpressed, triggering the activation of intracellular signaling cascades. These TRK fusion proteins act as oncogenic drivers, promoting tumor growth regardless of the tissue of origin.Tumordiffusion and growth.

Vitrakvi is a first-in-class oral TRK inhibitor. Its active pharmaceutical ingredient, larotrectinib, is a potent, oral, selective tropomyosin receptor kinase (TRK) inhibitor designed to directly target TRKs (including TRKA, TRKB, and TRKC), thereby shutting down the signaling pathways that drive the growth of TRK fusion-positive tumors. TRK fusion-drivenTumorIt can occur in various parts of the body, and conventional treatment regimens (such as surgery, chemotherapy, and radiotherapy) usually fail to achieve satisfactory therapeutic outcomes.

Vitrakvi is a histology-independent therapy specifically developed for the treatment of tumors harboring NTRK gene fusions, regardless of the tumor’s site of origin. In pediatric and adult patients with TRK fusion-positive cancers, Vitrakvi has demonstrated robust efficacy, including in primary central nervous system (CNS) tumors and brain metastases, providing high response rates and durable responses, irrespective of patient age andTumorHow is the histology?

In late November 2018, Vitrakvi received the world’s first approval in the United States, becoming the first orally administered TRK inhibitor ever approved, as well as the firstTumorTumor-agnostic, “basket” targeted anticancer drugs. Currently, Vitrakvi has been approved in many countries and regions around the world, including the European Union. (Bioon.com)

Original source: Bayer receivesapproval for Vitrakvi™ in Japan